-- a novel generation of biotech products to protect a wide spectrum of
crops from damage incurred from pests;
-- biotech traits and germplasm to meet the growing needs for high
yielding, high quality hybrid rice and selected small grains in India
and S.E. Asia;
-- safer and more environmentally friendly agro-chemical products to
protect crops from damage inflicted by plant parasitic nematodes.
Devgen's biopharmaceutical division develops a new class of preclinical drug candidates, based on novel therapeutic concepts, for treatment of a range of inflammatory metabolic diseases (diabetes, obesity) and arrhythmia.
Devgen has entered in partnerships with industry leaders in biotechnology and agro chemistry. Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore and Hyderabad (India), with a total work force of about 100 people. Devgen is listed on Eurolist by Euronext Brussels (ticker: DEVG) since June 2005. For more information on Devgen, please visit the company's web site: http://www.devgen.com.
Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. For more information on Monsanto, see: http://www.monsanto.com.
This press release may contain forward-looking statements containing
the words "anticipates," "expects," "intends," "plans," "estimates," "may"
and "continues" as well as similar expressions. Such forward looking
statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, performance or achievements
of Devgen to be materially different from any future results or
achievements expressed or implied by such forward-looking statements. These
forward looking statements sp
|SOURCE Monsanto Company|
Copyright©2007 PR Newswire.
All rights reserved